Z. Li
University of California, Riverside
ORCID: 0000-0002-8362-5617Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 8 papers. Top paper: “265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial”.
M. Gao, Y. Zhang, F. Shi, Y. Cheng, Z. Guo +14 more
G. Ye, T. Qiu, X. Liu, X. Wang, Z. Li +1 more
M. Thomas, S. Jacob, E. Lesser, Z. Li, C.K. Landolfo +10 more
R. Wesolowski, W. Osmani, Hans-Waldemar Brauer, A.s Sullivan, C. Hartl +24 more
Yanchen Wu, Yuzhuo Shao, Wei Cui, X. Zhu, Y. Huang +8 more
Yi Huang, Ta I Hung, Jianan Sun, Desiree Aispuro, Boxi Chen +9 more
L. Pessaint, J.P. Nkolola, A. Van Ry, S.H. Mahrokhian, G. Dagotto +63 more
Y. Zhao, M.K. Karuppan, M. Wang, Matthew J. Haney, Alexander V. Kabanov +7 more